Polyplus (part of Sartorius), an upstream solutions provider for advanced biologics and cell and gene therapy production from research to commercial grade has inked a collaboration with Korean cell and gene therapy (CGT) CDMO, MarkHerz to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product.
The teams will work to improve process efficiency leveraging Polyplus products and expertise with MarkHerz manufacturing capabilities. Proprietary e-Zyvec® technology will be used to design tailor-made plasmids for high-purity manufacturing. Plasmid engineering and production services will initiate the project, followed by upstream optimization.
Throughout this collaboration, the teams will also build and share local knowledge to help create a wider exchange of information and expertise to advance CGT manufacturing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!